Some of the names on the move ahead of the open.» Read More
This is a big week for the world's top-two biotechnology companies and their investors. What’s going on and how can you trade it?
Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.
This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.
In Friday’s Web Extra find out how the traders recommend playing Wal-Mart, Costco, Pfizer, Amgen and Genentech in the week ahead.
Nasdaq's bear market is likely to persist longer than the pullback in the broader stock market unless the recently battered technology heavyweights make solid comebacks.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...
Cramer makes the call on viewers' favorite stocks.
The time to buy stocks, says Michael Cuggino, is now. The president and portfolio manager of Permanent Portfolio Funds offered CNBC very specific reasons to buy -- and the specific stocks you need.
Perhaps this item belongs in the "Funny Business" blog of my witty colleague Jane Wells, but when I saw this headline cross the Dow Jones Newswire this afternoon under the "Market Talk" blurb they move several times during the trading day, I just had to throw it up on my blog. I didn't know DJ had hired "Linda Richman" to write copy, or maybe Mike Myers needs a little extra income.
Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.
Stocks are down this Valentine's Day, and there's nothing to love about that. To keep investors from getting their hearts broken by their portfolios, CNBC enlisted the help of market experts.
How should an investor play biotech stocks? Pay attention to individual events involving individual companies, according to Bear Stearns biotech analyst Mark Schoenebaum.
Amgen, the biggest biotech by revenue, is trying to regain investors' confidence after a 32% drop in the last year. How should you trade?
In their stump speeches and debates, Hillary Clinton and Barack Obama often talk about pushing back against the Washington influence of the powerful pharmaceutical lobby and keeping drug company profits in check.
It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.
In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.
A slew of strong earnings, good jobs data and a bounce in commodities kept stocks afloat for the second day in a row. And with Microsoft blowing away its numbers after the bell, the traders expect the rally to continue.
I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.
Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.